Ziagen (abacavir) approved: caution essential
- PMID: 11366148
Ziagen (abacavir) approved: caution essential
Abstract
AIDS: The Food and Drug Administration (FDA) announced accelerated approval of Glaxo-Wellcome's abacavir (Ziagen, 1592) in combination with other antiretrovirals. Abacavir is in the same nucleoside analog class as AZT, but abacavir has stronger effects against HIV. Use of the drug requires caution, because it can cause a serious hypersensitivity or allergic reaction in 5 percent of patients. If abacavir is stopped and restarted, the hypersensitivity can be more fatal. Little is known about long-term use of the drug or its effects when in combination with other anti-HIV medications other than AZT plus 3TC.
Similar articles
-
FDA approves abacavir. Food and Drug Administration.BETA. 1999 Jan;12(1):3. BETA. 1999. PMID: 11367235
-
Abacavir gets green light from FDA advisory board. Food and Drug Administration.TreatmentUpdate. 1998 Nov;10(9):3-4. TreatmentUpdate. 1998. PMID: 11365924 English, French.
-
Abacavir update.Proj Inf Perspect. 1998 Dec;(26):11. Proj Inf Perspect. 1998. PMID: 11366488
-
Management protocol for abacavir-related hypersensitivity reaction.Ann Pharmacother. 2000 Feb;34(2):247-9. doi: 10.1345/aph.19107. Ann Pharmacother. 2000. PMID: 10676833 Review.
-
Once-daily abacavir in place of twice-daily administration.Ann Pharmacother. 2005 Jul-Aug;39(7-8):1302-8. doi: 10.1345/aph.1E680. Epub 2005 Jun 14. Ann Pharmacother. 2005. PMID: 15956231 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical